肾内科指南

订阅

MedSci主页 / 所有栏目 / 肾内科指南

2021 NICE指南：慢性肾脏病的评估和管理（NG203）

2021-08-25 英国国家卫生与临床优化研究所 NICE官网

慢性肾脏病

2021年8月，英国国家卫生与临床优化研究所 (NICE)发布了慢性肾脏病的评估和管理指南，内容涵盖了慢性肾脏病（CKD）患者或者存在慢性肾脏病风险患者的护理和治疗，目的是预防或延缓疾病进展，减少并发

中文标题：

2021 NICE指南：慢性肾脏病的评估和管理（NG203）

英文标题：

NICE guideline [NG203]：Chronic kidney disease: assessment and management

发布机构：

英国国家卫生与临床优化研究所

发布日期：

2021-08-25

简要介绍：

2021年8月，英国国家卫生与临床优化研究所 (NICE)发布了慢性肾脏病的评估和管理指南，内容涵盖了慢性肾脏病（CKD）患者或者存在慢性肾脏病风险患者的护理和治疗，目的是预防或延缓疾病进展，减少并发症和心血管疾病风险，还涉及了慢性肾脏病相关贫血和高磷血症的管理。

相关资料下载：
[AttachmentFileName(sort=1, fileName=chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf)] GetToolGuiderByIdResponse(projectId=1, id=05cad1c002183ecb, title=2021 NICE指南：慢性肾脏病的评估和管理（NG203）, enTitle=NICE guideline [NG203]：Chronic kidney disease: assessment and management, guiderFrom=NICE官网, authorId=0, author=, summary=2021年8月，英国国家卫生与临床优化研究所 (NICE)发布了慢性肾脏病的评估和管理指南，内容涵盖了慢性肾脏病（CKD）患者或者存在慢性肾脏病风险患者的护理和治疗，目的是预防或延缓疾病进展，减少并发, cover=https://img.medsci.cn/2021911/1631373061776_5579292.jpg, journalId=0, articlesId=null, associationId=85, associationName=英国国家卫生与临床优化研究所, associationIntro=英国国家卫生与临床优化研究所（NICE，National Institute for Health and Clinical Excellence）是NHS的组织，设在伦敦和曼彻斯特。NICE成立于1999年4月1日，目标是确保每个英格兰和威尔士人平等享有NHS医疗的机会。NICE制定指南，设定质量标准，管理国家数据库，为NHS、当地权威部门和其他组织提供指南。, copyright=0, guiderPublishedTime=Wed Aug 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年8月，英国国家卫生与临床优化研究所 (NICE)发布了慢性肾脏病的评估和管理指南，内容涵盖了慢性肾脏病（CKD）患者或者存在慢性肾脏病风险患者的护理和治疗，目的是预防或延缓疾病进展，减少并发症和心血管疾病风险，还涉及了慢性肾脏病相关贫血和高磷血症的管理。</span></p>, tagList=[TagDto(tagId=2527, tagName=慢性肾脏病)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2527, guiderKeyword=慢性肾脏病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5154, appHits=360, showAppHits=0, pcHits=968, showPcHits=4794, likes=1, shares=32, comments=4, approvalStatus=1, publishedTime=Mon Sep 13 00:04:09 CST 2021, publishedTimeString=2021-08-25, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Sep 11 23:10:13 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 18:57:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf)])
chronic-kidney-disease-assessment-and-management-pdf-66143713055173.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1236182, encodeId=c4cb1236182ce, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0e78212025, createdName=ms6000001039842751, createdTime=Tue Aug 02 17:15:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193403, encodeId=b352119340333, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e55314409, createdName=14894ae8m52暂无昵称, createdTime=Mon Feb 14 20:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064084, encodeId=3f0d106408474, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Tue Oct 26 14:33:00 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061200, encodeId=5ddc10612008c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d6f2827005, createdName=370763566, createdTime=Sun Oct 17 11:48:02 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2022-08-02 ms6000001039842751

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1236182, encodeId=c4cb1236182ce, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0e78212025, createdName=ms6000001039842751, createdTime=Tue Aug 02 17:15:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193403, encodeId=b352119340333, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e55314409, createdName=14894ae8m52暂无昵称, createdTime=Mon Feb 14 20:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064084, encodeId=3f0d106408474, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Tue Oct 26 14:33:00 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061200, encodeId=5ddc10612008c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d6f2827005, createdName=370763566, createdTime=Sun Oct 17 11:48:02 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2022-02-14 14894ae8m52暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1236182, encodeId=c4cb1236182ce, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0e78212025, createdName=ms6000001039842751, createdTime=Tue Aug 02 17:15:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193403, encodeId=b352119340333, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e55314409, createdName=14894ae8m52暂无昵称, createdTime=Mon Feb 14 20:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064084, encodeId=3f0d106408474, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Tue Oct 26 14:33:00 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061200, encodeId=5ddc10612008c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d6f2827005, createdName=370763566, createdTime=Sun Oct 17 11:48:02 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-26 ms6000001387765207

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1236182, encodeId=c4cb1236182ce, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a0e78212025, createdName=ms6000001039842751, createdTime=Tue Aug 02 17:15:39 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193403, encodeId=b352119340333, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60e55314409, createdName=14894ae8m52暂无昵称, createdTime=Mon Feb 14 20:44:01 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064084, encodeId=3f0d106408474, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47445626421, createdName=ms6000001387765207, createdTime=Tue Oct 26 14:33:00 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061200, encodeId=5ddc10612008c, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d6f2827005, createdName=370763566, createdTime=Sun Oct 17 11:48:02 CST 2021, time=2021-10-17, status=1, ipAttribution=)]
    2021-10-17 370763566

    谢谢

    0

相关指南

慢性肾脏病继发甲状旁腺功能亢进外科临床实践中国专家共识（2021版）

中国医师协会外科医师分会 甲状腺外科医师委员会 · 2021-08-01

2021 G-CAN 共识声明：慢性肾脏病痛风的管理

痛风、高尿酸血症和晶体相关疾病网络（Gout, Hyperuricemia and Crystal-Associated Disease Network, G-CAN） · 2021-07-30

2021 ERA-EDTA/ERKNet实践建议：基因检测在慢性肾脏病诊断中的应用

欧洲肾脏学会-欧洲透析和移植学会(ERA-EDTA,European Renal Association&ndash;European Dialysis and Transplant Association) · 2021-07-15

2021 KDIGO临床实践指南：慢性肾脏病患者的血压管理

改善全球肾脏病预后组织(KDIGO,Kidney Disease: Improving Global Outcomes) · 2021-02-23

NICE指南：新冠肺炎期间慢性肾脏病

国家卫生和护理研究所（NICE） · 2020-05-15

慢性肾脏病高钾血症风险评估及管理专家建议（2020版）

肾脏病相关专家小组（统称） · 2020-12-01

拓展阅读

2015慢性肾脏病评估及管理临床实践指南解读——从 K/DOQI 到 KDIGO

国际肾脏病学会(ISN,International Society of Nephrology) · 2016-04-25

2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识（2015年更新版）

中国医师协会内分泌代谢科医师分会 · 2016-06-30

2015 NICE指南：慢性肾脏病：贫血管理（NG8）

暂未更新 · 2015-06-03

中国成人慢性肾脏病合并结核病管理专家共识

暂未更新 · 2016-11-30

慢性肾脏病筛查诊断及防治指南

肾脏病相关专家小组（统称） · 2017-01-30

HIV感染合并慢性肾脏病患者管理专家共识

中国感染病相关专家组（统称） · 2017-06-15